Karl X. Chai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karl X. Chai has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Li-Mei Chen
Burnett School of Biomedical Sciences, Division of Cancer Research, University of Central Florida College of Medicine, Orlando, FL 32816-2364, USA
6 shared publicationsLi‐Mei Chen
Department of Molecular Biology and Microbiology, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida, USA
4 shared publicationsMengqian Chen
Department of Molecular Biology and Microbiology, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL 32816-2364, USA
4 shared publicationsChen-Yong Lin
University of Maryland School of Medicine
3 shared publications- Amanda McCann
University College Dublin
1 shared publication Charles J. Rosser
Cancer Research Institute, M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States of America
1 shared publication
Latest Publications
- Open Access
- 3 January 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 5
Matriptase cleaves the amyloid-beta peptide 1–42 at Arg-5, Lys-16, and Lys-28
The type-II transmembrane extracellular serine protease matriptase was shown to cleave at Arg-102 in the amino-terminal region of the amyloid precursor protein (APP). In this study we determined matriptase cleavage sites in the amyloid-beta (Aβ) peptide region of APP (Asp-597 to Ala-638 in the APP695 isoform). A recombinant human matriptase protease domain was used to cleave a synthetic human Aβ1–42 peptide. The human APP695 or mutants at the candidate matriptase cleavage sites was co-expressed with the human matriptase or its protease-dead mutant in HEK293 cells to evaluate matriptase cleavage of APP. Overexpression of matriptase in the M17 human neuroblastoma cells was performed to determine the effect of matriptase expression on endogenous APP. The human Aβ1–42 peptide can be cleaved by the matriptase serine protease domain, at Arg-5, Lys-16, and Lys-28, as determined by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Co-expression of matriptase but not its protease-dead mutant with APP695 resulted in site-specific cleavages of the latter. Replacement of Arg-601 (Arg-5 in Aβ1–42) by Ala in APP695 prevented matriptase cleavage at this site. Overexpression of matriptase but not its protease-dead mutant in the M17 cells resulted in a significant reduction of the endogenous APP quantity.
- 3 January 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 5
Open AccessMatriptase cleaves the amyloid-beta peptide 1–42 at Arg-5, Lys-16, and Lys-28
The type-II transmembrane extracellular serine protease matriptase was shown to cleave at Arg-102 in the amino-terminal region of the amyloid precursor protein (APP). In this study we determined matriptase cleavage sites in the amyloid-beta (Aβ) peptide region of APP (Asp-597 to Ala-638 in the APP695 isoform). A recombinant human matriptase protease domain was used to cleave a synthetic human Aβ1–42 peptide. The human APP695 or mutants at the candidate matriptase cleavage sites was co-expressed with the human matriptase or its protease-dead mutant in HEK293 cells to evaluate matriptase cleavage of APP. Overexpression of matriptase in the M17 human neuroblastoma cells was performed to determine the effect of matriptase expression on endogenous APP. The human Aβ1–42 peptide can be cleaved by the matriptase serine protease domain, at Arg-5, Lys-16, and Lys-28, as determined by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Co-expression of matriptase but not its protease-dead mutant with APP695 resulted in site-specific cleavages of the latter. Replacement of Arg-601 (Arg-5 in Aβ1–42) by Ala in APP695 prevented matriptase cleavage at this site. Overexpression of matriptase but not its protease-dead mutant in the M17 cells resulted in a significant reduction of the endogenous APP quantity.
- Open Access
- 10 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (34) , 56490-56505
Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases
Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases
- 10 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (34) , 56490-56505
Open AccessProteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases
Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases
- Open Access
- 28 May 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e65513
Long-Term Exposure to Cigarette Smoke Extract Induces Hypomethylation at the RUNX3 and IGF2-H19 Loci in Immortalized Human Urothelial Cells
Cigarette smoking is the single most important epidemiological risk factor for bladder cancer but it is not known whether exposure of urothelial cells to the systemic soluble contents of cigarette smoke is directly causative to bladder cancer and the associated epigenetic changes such as tumor suppressor gene hypermethylation. We undertook this study to investigate if long-term treatment of human urothelial cells with cigarette smoke extract (CSE) results in tumor suppressor gene hypermethylation, a phenotype that was previously associated with long-term constant CSE treatment of airway epithelial cells. We chronically treated an immortalized human urothelial cell line UROtsa with CSE using a cyclic daily regimen but the cells were cultured in CSE-free medium between daily treatments. Bisulfite sequencing and real-time PCR array-based methylation profiling were employed to evaluate methylation changes at tumor suppressor gene loci in the chronically CSE-treated cells versus the passage-matched untreated control cells. The RUNX3 tumor suppressor gene promoter was hypomethylated with a significant increase in proportion of the completely unmethylated haplotype after the long-term CSE treatment; whereas RUNX3 promoter hypermethylation was previously reported for bladder cancers of smokers. Hypomethylation induced by the long-term CSE treatment was also observed for the IGF2-H19 locus. The methylation status at the PRSS8/prostasin and 16 additional loci however, was unaffected by the chronic CSE treatment. Transient CSE treatment over 1 daily regimen resulted in transcriptional down-regulation of RUNX3 and H19, but only the H19 transcription was down-regulated in the chronically CSE-treated urothelial cells. Transcription of a key enzyme in one-carbon metabolism, dihydrofolate reductase (DHFR) was greatly reduced by the long-term CSE treatment, potentially serving as a mechanism for the hypomethylation phenotype via a reduced supply of methyl donor. In conclusion, chronic cyclic CSE treatment of urothelial cells induced hypomethylation rather than hypermethylation at specific loci.
- 28 May 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e65513
Open AccessLong-Term Exposure to Cigarette Smoke Extract Induces Hypomethylation at the RUNX3 and IGF2-H19 Loci in Immortalized Human Urothelial Cells
Cigarette smoking is the single most important epidemiological risk factor for bladder cancer but it is not known whether exposure of urothelial cells to the systemic soluble contents of cigarette smoke is directly causative to bladder cancer and the associated epigenetic changes such as tumor suppressor gene hypermethylation. We undertook this study to investigate if long-term treatment of human urothelial cells with cigarette smoke extract (CSE) results in tumor suppressor gene hypermethylation, a phenotype that was previously associated with long-term constant CSE treatment of airway epithelial cells. We chronically treated an immortalized human urothelial cell line UROtsa with CSE using a cyclic daily regimen but the cells were cultured in CSE-free medium between daily treatments. Bisulfite sequencing and real-time PCR array-based methylation profiling were employed to evaluate methylation changes at tumor suppressor gene loci in the chronically CSE-treated cells versus the passage-matched untreated control cells. The RUNX3 tumor suppressor gene promoter was hypomethylated with a significant increase in proportion of the completely unmethylated haplotype after the long-term CSE treatment; whereas RUNX3 promoter hypermethylation was previously reported for bladder cancers of smokers. Hypomethylation induced by the long-term CSE treatment was also observed for the IGF2-H19 locus. The methylation status at the PRSS8/prostasin and 16 additional loci however, was unaffected by the chronic CSE treatment. Transient CSE treatment over 1 daily regimen resulted in transcriptional down-regulation of RUNX3 and H19, but only the H19 transcription was down-regulated in the chronically CSE-treated urothelial cells. Transcription of a key enzyme in one-carbon metabolism, dihydrofolate reductase (DHFR) was greatly reduced by the long-term CSE treatment, potentially serving as a mechanism for the hypomethylation phenotype via a reduced supply of methyl donor. In conclusion, chronic cyclic CSE treatment of urothelial cells induced hypomethylation rather than hypermethylation at specific loci.
- Open Access
- 1 January 2010
- Published by Hindawi Limited in Journal of Biomedicine and Biotechnology
- Vol. 2010, 1
The Epithelium—Molecular Landscaping for an Interactive Barrier
- 1 January 2010
- Published by Hindawi Limited in Journal of Biomedicine and Biotechnology
- Vol. 2010, 1
Open AccessThe Epithelium—Molecular Landscaping for an Interactive Barrier
- 13 November 2009
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 337 (1-2) , 259-266
Hepsin activates prostasin and cleaves the extracellular domain of the epidermal growth factor receptor
The epithelial extracellular serine protease activation cascade involves matriptase (PRSS14) and prostasin (PRSS8), capable of modulating epidermal growth factor receptor (EGFR) signaling. Matriptase activates prostasin by cleaving in the amino-terminal pro-peptide region of prostasin, presumably at the Arg residue of position 44 (R44) of the full-length human prostasin. Using an Arg-to-Ala mutant (R44A) human prostasin, we showed in this report that the cleavage of prostasin by matriptase is at Arg44. This prostasin proteolytic activation site is also cleaved by hepsin (TMPRSS1) to produce active prostasin capable of forming a covalent complex with protease nexin 1 (PN-1). An amino-terminal truncation of EGFR in the extracellular domain (ECD) was observed when the receptor was co-expressed with hepsin. Hepsin and matriptase appear to cleave the EGFR ECD at different sites, while the hepsin cleavage is not affected by active prostasin, which enhances the matriptase cleavage of EGFR. Using hepsin as the prostasin-activating protease in cells co-transfected with EGFR, we showed that active prostasin does not cleave the EGFR ECD directly in the cellular context. Purified active prostasin also does not cleave purified EGFR. Hepsin cleavage of EGFR is not dependent on receptor tyrosine phosphorylation, while the hepsin-cleaved EGFR is phosphorylated at Tyr1068 and no longer responsive to EGF stimulation. The cleavage of EGFR by hepsin does not result in increased phosphorylation of the downstream extracellular signal-regulated kinases (Erk1/2), an event inducible by the matriptase–prostasin cleavage of EGFR. The role of hepsin serine protease should be considered in future studies of epithelial biology concerning matriptase, prostasin, and EGFR.
- 13 November 2009
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 337 (1-2) , 259-266
Hepsin activates prostasin and cleaves the extracellular domain of the epidermal growth factor receptor
The epithelial extracellular serine protease activation cascade involves matriptase (PRSS14) and prostasin (PRSS8), capable of modulating epidermal growth factor receptor (EGFR) signaling. Matriptase activates prostasin by cleaving in the amino-terminal pro-peptide region of prostasin, presumably at the Arg residue of position 44 (R44) of the full-length human prostasin. Using an Arg-to-Ala mutant (R44A) human prostasin, we showed in this report that the cleavage of prostasin by matriptase is at Arg44. This prostasin proteolytic activation site is also cleaved by hepsin (TMPRSS1) to produce active prostasin capable of forming a covalent complex with protease nexin 1 (PN-1). An amino-terminal truncation of EGFR in the extracellular domain (ECD) was observed when the receptor was co-expressed with hepsin. Hepsin and matriptase appear to cleave the EGFR ECD at different sites, while the hepsin cleavage is not affected by active prostasin, which enhances the matriptase cleavage of EGFR. Using hepsin as the prostasin-activating protease in cells co-transfected with EGFR, we showed that active prostasin does not cleave the EGFR ECD directly in the cellular context. Purified active prostasin also does not cleave purified EGFR. Hepsin cleavage of EGFR is not dependent on receptor tyrosine phosphorylation, while the hepsin-cleaved EGFR is phosphorylated at Tyr1068 and no longer responsive to EGF stimulation. The cleavage of EGFR by hepsin does not result in increased phosphorylation of the downstream extracellular signal-regulated kinases (Erk1/2), an event inducible by the matriptase–prostasin cleavage of EGFR. The role of hepsin serine protease should be considered in future studies of epithelial biology concerning matriptase, prostasin, and EGFR.
- Open Access
- 22 October 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 377
Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT)
Background: The glycosylphosphatidylinositol (GPI)-anchored epithelial extracellular membrane serine protease prostasin (PRSS8) is expressed abundantly in normal epithelia and essential for terminal epithelial differentiation, but down-regulated in human prostate, breast, and gastric cancers and invasive cancer cell lines. Prostasin is involved in the extracellular proteolytic modulation of the epidermal growth factor receptor (EGFR) and is an invasion suppressor. The aim of this study was to evaluate prostasin expression states in the transitional cell carcinomas (TCC) of the human bladder and in human TCC cell lines. Methods: Normal human bladder tissues and TCC on a bladder cancer tissue microarray (TMA) were evaluated for prostasin expression by means of immunohistochemistry. A panel of 16 urothelial and TCC cell lines were evaluated for prostasin and E-cadherin expression by western blot and quantitative PCR, and for prostasin gene promoter region CpG methylation by methylation-specific PCR (MSP). Results: Prostasin is expressed in the normal human urothelium and in a normal human urothelial cell line, but is significantly down-regulated in high-grade TCC and lost in 9 (of 15) TCC cell lines. Loss of prostasin expression in the TCC cell lines correlated with loss of or reduced E-cadherin expression, loss of epithelial morphology, and promoter DNA hypermethylation. Prostasin expression could be reactivated by demethylation or inhibition of histone deacetylase. Re-expression of prostasin or a serine protease-inactive variant resulted in transcriptional up-regulation of E-cadherin. Conclusion: Loss of prostasin expression in bladder transitional cell carcinomas is associated with epithelial-mesenchymal transition (EMT), and may have functional implications in tumor invasion and resistance to chemotherapy.
- 22 October 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 377
Open AccessLoss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT)
Background: The glycosylphosphatidylinositol (GPI)-anchored epithelial extracellular membrane serine protease prostasin (PRSS8) is expressed abundantly in normal epithelia and essential for terminal epithelial differentiation, but down-regulated in human prostate, breast, and gastric cancers and invasive cancer cell lines. Prostasin is involved in the extracellular proteolytic modulation of the epidermal growth factor receptor (EGFR) and is an invasion suppressor. The aim of this study was to evaluate prostasin expression states in the transitional cell carcinomas (TCC) of the human bladder and in human TCC cell lines. Methods: Normal human bladder tissues and TCC on a bladder cancer tissue microarray (TMA) were evaluated for prostasin expression by means of immunohistochemistry. A panel of 16 urothelial and TCC cell lines were evaluated for prostasin and E-cadherin expression by western blot and quantitative PCR, and for prostasin gene promoter region CpG methylation by methylation-specific PCR (MSP). Results: Prostasin is expressed in the normal human urothelium and in a normal human urothelial cell line, but is significantly down-regulated in high-grade TCC and lost in 9 (of 15) TCC cell lines. Loss of prostasin expression in the TCC cell lines correlated with loss of or reduced E-cadherin expression, loss of epithelial morphology, and promoter DNA hypermethylation. Prostasin expression could be reactivated by demethylation or inhibition of histone deacetylase. Re-expression of prostasin or a serine protease-inactive variant resulted in transcriptional up-regulation of E-cadherin. Conclusion: Loss of prostasin expression in bladder transitional cell carcinomas is associated with epithelial-mesenchymal transition (EMT), and may have functional implications in tumor invasion and resistance to chemotherapy.
- 7 August 2009
- Published by Wiley in The Prostate
- Vol. 69 (16) , 1790-1801
Prostasin regulates iNOS and cyclin D1 expression by modulating protease‐activated receptor‐2 signaling in prostate epithelial cells
BACKGROUND: Prostasin is down‐regulated during inflammation and in invasive cancers, and plays a role in regulation of inflammatory gene expression and invasion.METHODS: We used the human benign prostatic hyperplasia cell line BPH‐1 to investigate gene expression changes associated with siRNA‐mediated loss of prostasin expression. Quantitative PCR and/or western blotting were used to evaluate the expression changes of iNOS, ICAM‐1, cyclin D1, IL‐6, and IL‐8. Gene expression changes were also evaluated in the presence of a PAR‐2 antagonist. The PC‐3 human prostate cancer cell line was used for evaluation of gene expression in response to prostasin re‐expression.RESULTS: Prostasin silencing in BPH‐1 was associated with up‐regulation of iNOS, ICAM‐1, IL‐6, and IL‐8, and down‐regulation of cyclin D1; as well as reduced proliferation and invasion. The iNOS up‐regulation and cyclin D1 down‐regulation associated with prostasin silencing were inhibited by a PAR‐2 antagonist. Re‐expression of prostasin, a serine active‐site mutant, and a GPI‐anchor‐free mutant, in the PC‐3 cells resulted in PAR‐2 and cyclin D1 transcription up‐regulation. Transcription up‐regulation of IL‐6 and IL‐8 was associated with re‐expression of the serine active‐site mutant prostasin in the PC‐3 cells. Transcription up‐regulation of IL‐8, but to a lesser extent, was also observed in PC‐3 cells expressing the wild‐type prostasin. Expression of a serine protease active prostasin, GPI‐anchored or anchor‐free, prevented the IL‐6 induction in response to PAR‐2. The GPI‐anchor‐free prostasin also prevented the IL‐8 induction.CONCLUSIONS: Prostasin plays a negative regulatory role on PAR‐2‐mediated signaling in prostate epithelial cells. Prostate 69: 1790–1801, 2009.
- 7 August 2009
- Published by Wiley in The Prostate
- Vol. 69 (16) , 1790-1801
Prostasin regulates iNOS and cyclin D1 expression by modulating protease‐activated receptor‐2 signaling in prostate epithelial cells
BACKGROUND: Prostasin is down‐regulated during inflammation and in invasive cancers, and plays a role in regulation of inflammatory gene expression and invasion.METHODS: We used the human benign prostatic hyperplasia cell line BPH‐1 to investigate gene expression changes associated with siRNA‐mediated loss of prostasin expression. Quantitative PCR and/or western blotting were used to evaluate the expression changes of iNOS, ICAM‐1, cyclin D1, IL‐6, and IL‐8. Gene expression changes were also evaluated in the presence of a PAR‐2 antagonist. The PC‐3 human prostate cancer cell line was used for evaluation of gene expression in response to prostasin re‐expression.RESULTS: Prostasin silencing in BPH‐1 was associated with up‐regulation of iNOS, ICAM‐1, IL‐6, and IL‐8, and down‐regulation of cyclin D1; as well as reduced proliferation and invasion. The iNOS up‐regulation and cyclin D1 down‐regulation associated with prostasin silencing were inhibited by a PAR‐2 antagonist. Re‐expression of prostasin, a serine active‐site mutant, and a GPI‐anchor‐free mutant, in the PC‐3 cells resulted in PAR‐2 and cyclin D1 transcription up‐regulation. Transcription up‐regulation of IL‐6 and IL‐8 was associated with re‐expression of the serine active‐site mutant prostasin in the PC‐3 cells. Transcription up‐regulation of IL‐8, but to a lesser extent, was also observed in PC‐3 cells expressing the wild‐type prostasin. Expression of a serine protease active prostasin, GPI‐anchored or anchor‐free, prevented the IL‐6 induction in response to PAR‐2. The GPI‐anchor‐free prostasin also prevented the IL‐8 induction.CONCLUSIONS: Prostasin plays a negative regulatory role on PAR‐2‐mediated signaling in prostate epithelial cells. Prostate 69: 1790–1801, 2009.
- 1 July 2007
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1773 (7) , 1133-1140
Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3
- 1 July 2007
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1773 (7) , 1133-1140
Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3
- 15 March 2006
- Published by Wiley in The Prostate
- Vol. 66 (9) , 911-920
Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG
BACKGROUND Prostasin is downregulated in hormone-refractory prostate cancers (HRPC). The mechanisms by which androgens regulate prostasin expression are unclear. METHODS LNCaP cells were treated with dihydrotestosterone (DHT), and mRNA expression of prostasin, SREBPs, SNAIL, and SLUG was examined by real-time PCR following reverse transcription. A human prostasin promoter was evaluated in HEK-293 cells co-transfected with transcription factor cDNAs. Regulation of endogenous prostasin expression by transfected SREBP-2 or SLUG was evaluated. Expression of SNAIL and SLUG mRNA in DU-145 cells treated with epidermal growth factor (EGF) was examined. RESULTS Prostasin mRNA expression in LNCaP cells was not responsive to DHT treatment. DHT marginally upregulated mRNA expression of SREBP-1c, SREBP-2, and SNAIL, but not SREBP-1a, while dramatically increased SLUG mRNA expression, in a dose-dependent manner. Co-transfection of prostasin promoter and SREBP cDNA in HEK-293 cells resulted in stimulation of promoter activity at ∼twofold by SREBP-1c, and up to sixfold by SREBP-2; while co-transfection with SNAIL or SLUG cDNA resulted in repression of promoter activity to 43% or 59%, respectively. Co-transfection of the SLUG cDNA negated SREBP-2's stimulation of prostasin promoter in a dose-dependent manner. Transfection of an SREBP-2 cDNA in HEK-293 and DU-145 resulted in upregulation of prostasin while transfection of a SLUG cDNA in LNCaP repressed prostasin expression. EGF upregulated SNAIL and SLUG mRNA in DU-145. CONCLUSIONS DHT regulates prostasin expression in prostate cells via SREBP stimulation and SLUG repression of prostasin promoter. SLUG is upregulated by DHT and EGF, providing a molecular mechanism by which epithelial cell-specific genes are silenced during prostate cancer development and progression. Prostate 66: 911–920, 2006.
- 15 March 2006
- Published by Wiley in The Prostate
- Vol. 66 (9) , 911-920
Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG
BACKGROUND Prostasin is downregulated in hormone-refractory prostate cancers (HRPC). The mechanisms by which androgens regulate prostasin expression are unclear. METHODS LNCaP cells were treated with dihydrotestosterone (DHT), and mRNA expression of prostasin, SREBPs, SNAIL, and SLUG was examined by real-time PCR following reverse transcription. A human prostasin promoter was evaluated in HEK-293 cells co-transfected with transcription factor cDNAs. Regulation of endogenous prostasin expression by transfected SREBP-2 or SLUG was evaluated. Expression of SNAIL and SLUG mRNA in DU-145 cells treated with epidermal growth factor (EGF) was examined. RESULTS Prostasin mRNA expression in LNCaP cells was not responsive to DHT treatment. DHT marginally upregulated mRNA expression of SREBP-1c, SREBP-2, and SNAIL, but not SREBP-1a, while dramatically increased SLUG mRNA expression, in a dose-dependent manner. Co-transfection of prostasin promoter and SREBP cDNA in HEK-293 cells resulted in stimulation of promoter activity at ∼twofold by SREBP-1c, and up to sixfold by SREBP-2; while co-transfection with SNAIL or SLUG cDNA resulted in repression of promoter activity to 43% or 59%, respectively. Co-transfection of the SLUG cDNA negated SREBP-2's stimulation of prostasin promoter in a dose-dependent manner. Transfection of an SREBP-2 cDNA in HEK-293 and DU-145 resulted in upregulation of prostasin while transfection of a SLUG cDNA in LNCaP repressed prostasin expression. EGF upregulated SNAIL and SLUG mRNA in DU-145. CONCLUSIONS DHT regulates prostasin expression in prostate cells via SREBP stimulation and SLUG repression of prostasin promoter. SLUG is upregulated by DHT and EGF, providing a molecular mechanism by which epithelial cell-specific genes are silenced during prostate cancer development and progression. Prostate 66: 911–920, 2006.